TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced the initiation of a Phase 2a clinical trial evaluating its lead therapeutic candidate, TTX-MC138, in up to 45 colorectal cancer patients who remain circulating tumor DNA-positive following curative-intent therapy despite no radiographic evidence of disease, indicating minimal residual disease. The trial is conducted in collaboration with Quantum Leap Healthcare Collaborative through its PRE-I-SPY clinical trial platform, and will assess the biological and clinical activity of TTX-MC138 in reducing recurrence risk in this high-risk patient population.
TTX-MC138 is designed to target metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. By focusing on patients with minimal residual disease, the trial aims to intervene early and potentially prevent relapse. The study's primary endpoint will evaluate the reduction of circulating tumor DNA levels, a surrogate marker for residual disease. Secondary endpoints include safety, tolerability, and progression-free survival.
The initiation of this trial marks a significant step for TransCode Therapeutics, as it advances its RNA-based therapeutic platform into later-stage clinical development. The company is a clinical-stage firm pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. In addition to TTX-MC138, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
The collaboration with Quantum Leap Healthcare Collaborative provides access to an established clinical trial infrastructure, which may accelerate patient enrollment and data collection. The PRE-I-SPY platform is known for adaptive trial designs that allow for efficient evaluation of multiple therapies. This partnership could enhance the robustness of the trial results and facilitate future regulatory interactions.
For investors, this development is noteworthy as it demonstrates TransCode's progress in advancing its pipeline. The company's focus on a specific biomarker and patient population addresses a high unmet medical need. However, the trial's success is not guaranteed, and investors should monitor upcoming data releases. For more information, the full press release is available at https://ibn.fm/wuRri. Latest news and updates relating to RNAZ are available in the company's newsroom at https://ibn.fm/RNAZ.
